Successful treatment of metastatic rhabdomyosarcoma with radiochemotherapy and allogeneic hematopoietic stem cell transplantation

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We report a case of a 21-year-old man with alveolar rhabdomyosarcoma primarily in the right hand with lymph node, lung, bone and bone marrow metastases. Complete remission was achieved after intensive chemotherapy and radiotherapy of the primary and metastatic sites, followed by allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning from a single HLA-DR locus-mismatched mother. The patient remained relapse-free for 41 months after the diagnosis. Considering that the conventional treatment for rhabdomyosarcoma with multiple risk factors (old age, bone or bone marrow involvement, unfavorable primary sites and ≥3 metastases) is associated with a poor prognosis (5% probability of a 3-year event-free survival), the graft-versus-tumor effect may have contributed to his sustained relapse-free survival. Allogeneic hematopoietic stem cell transplantation for rhabdomyosarcoma should be done by experienced clinical oncologists on properly designed controlled trials.

Original languageEnglish
Pages (from-to)225-228
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume45
Issue number2
DOIs
Publication statusPublished - 2015 Feb 1

Fingerprint

Rhabdomyosarcoma
Hematopoietic Stem Cell Transplantation
Chemoradiotherapy
Bone Marrow
Alveolar Rhabdomyosarcoma
Neoplasm Metastasis
Peripheral Blood Stem Cell Transplantation
Bone and Bones
Recurrence
HLA-DR Antigens
Disease-Free Survival
Radiotherapy
Hand
Lymph Nodes
Mothers
Transplants
Drug Therapy
Lung
Survival
Therapeutics

Keywords

  • Chemotherapy
  • Rhabdomyosarcoma
  • Stem cell transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

@article{ca90bcc9208747bc8e789d100549e610,
title = "Successful treatment of metastatic rhabdomyosarcoma with radiochemotherapy and allogeneic hematopoietic stem cell transplantation",
abstract = "We report a case of a 21-year-old man with alveolar rhabdomyosarcoma primarily in the right hand with lymph node, lung, bone and bone marrow metastases. Complete remission was achieved after intensive chemotherapy and radiotherapy of the primary and metastatic sites, followed by allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning from a single HLA-DR locus-mismatched mother. The patient remained relapse-free for 41 months after the diagnosis. Considering that the conventional treatment for rhabdomyosarcoma with multiple risk factors (old age, bone or bone marrow involvement, unfavorable primary sites and ≥3 metastases) is associated with a poor prognosis (5{\%} probability of a 3-year event-free survival), the graft-versus-tumor effect may have contributed to his sustained relapse-free survival. Allogeneic hematopoietic stem cell transplantation for rhabdomyosarcoma should be done by experienced clinical oncologists on properly designed controlled trials.",
keywords = "Chemotherapy, Rhabdomyosarcoma, Stem cell transplantation",
author = "Fumito Yamazaki and Tomoo Osumi and Naoyuki Shigematsu and Hideo Morioka and Hiroyuki Shimada",
year = "2015",
month = "2",
day = "1",
doi = "10.1093/jjco/hyu189",
language = "English",
volume = "45",
pages = "225--228",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Successful treatment of metastatic rhabdomyosarcoma with radiochemotherapy and allogeneic hematopoietic stem cell transplantation

AU - Yamazaki, Fumito

AU - Osumi, Tomoo

AU - Shigematsu, Naoyuki

AU - Morioka, Hideo

AU - Shimada, Hiroyuki

PY - 2015/2/1

Y1 - 2015/2/1

N2 - We report a case of a 21-year-old man with alveolar rhabdomyosarcoma primarily in the right hand with lymph node, lung, bone and bone marrow metastases. Complete remission was achieved after intensive chemotherapy and radiotherapy of the primary and metastatic sites, followed by allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning from a single HLA-DR locus-mismatched mother. The patient remained relapse-free for 41 months after the diagnosis. Considering that the conventional treatment for rhabdomyosarcoma with multiple risk factors (old age, bone or bone marrow involvement, unfavorable primary sites and ≥3 metastases) is associated with a poor prognosis (5% probability of a 3-year event-free survival), the graft-versus-tumor effect may have contributed to his sustained relapse-free survival. Allogeneic hematopoietic stem cell transplantation for rhabdomyosarcoma should be done by experienced clinical oncologists on properly designed controlled trials.

AB - We report a case of a 21-year-old man with alveolar rhabdomyosarcoma primarily in the right hand with lymph node, lung, bone and bone marrow metastases. Complete remission was achieved after intensive chemotherapy and radiotherapy of the primary and metastatic sites, followed by allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning from a single HLA-DR locus-mismatched mother. The patient remained relapse-free for 41 months after the diagnosis. Considering that the conventional treatment for rhabdomyosarcoma with multiple risk factors (old age, bone or bone marrow involvement, unfavorable primary sites and ≥3 metastases) is associated with a poor prognosis (5% probability of a 3-year event-free survival), the graft-versus-tumor effect may have contributed to his sustained relapse-free survival. Allogeneic hematopoietic stem cell transplantation for rhabdomyosarcoma should be done by experienced clinical oncologists on properly designed controlled trials.

KW - Chemotherapy

KW - Rhabdomyosarcoma

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84922445319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922445319&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu189

DO - 10.1093/jjco/hyu189

M3 - Article

VL - 45

SP - 225

EP - 228

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -